June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.
August 2016 in “Journal of Investigative Dermatology” This study observed that uncommon finasteride side effects included melasma, dry skin, tinnitus, postural hypotension, and oral lesions, with some symptoms persisting after treatment cessation.
August 2016 in “Journal of Investigative Dermatology” This study found that adverse effects of finasteride were more common among right-handed heterosexuals and left-handed homosexuals with androgenic alopecia.
August 2016 in “Journal of Investigative Dermatology” This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.
August 2016 in “Journal of Investigative Dermatology” This study observed that the osteopontin-derived peptide FOL-005 inhibited hair growth in human scalp skin models, contrary to its hair growth promotion in mice, supporting further clinical testing for excessive hair growth treatment.